Sunitinib (SU11248) it is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vegf receptors 1, 2, 3, and pdgfra and pdgfrb. Here, PDGFRB is linked to neoplasm.